Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 33

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 33
---
 existing information, we may ask that such patents be reexamined or reissued, as applicable, by the United States Patent
and Trademark Office.

Because we rely heavily
on patent protection, we face the following significant risks:

| ● | Possibility of Inadequate Patent Protection for Product. The United States Patent and Trademark Office or foreign patent offices may not grant patents of meaningful scope based on the applications we have already filed and those we intend to file. If we do not have patents that adequately protect our human-use equipment and indications for its use, then we will not be competitive. |

| ● | Potential                                                                                                                                 
 That Important Patents Will Be Judged Invalid. Some of the issued patents (issued patents cannot be invalid only provisional              
 applications or know-how we now own or license may be determined to be invalid. If we have to defend the validity of any of our patents,  
 the costs of such defense could be substantial, and there is no guarantee of a successful outcome. In the event an important patent       
 related to our drug delivery technology is found to be invalid, we may lose competitive position and may not be able to receive royalties 
 for products covered in part or whole by that patent under license agreements.                                                            |

| ● | Danger                                                                                                                                  
 of Being Charged with Infringement. Although we are not currently aware of any parties intending to pursue infringement claims          
 against us, there is the possibility that we may use a patented technology owned by another person and/or be charged with infringement. 
 Defending or indemnifying a third party against a charge of infringement can involve lengthy and costly legal actions, and there        
 can be no guarantee of a successful outcome. Biotechnology companies comparable to us in size and financial position have discontinued  
 business after losing infringement battles. If we or our partners were prevented from using or selling our human-use equipment, then    
 our business would be materially adversely affected.                                                                                    |

| ● | Freedom to Operate Issues. The competitive nature of our field of business and the fact that others have sought patent protection for technologies similar to ours make these potential issues significant. |

In addition to patents,
we also rely on trade secrets and proprietary know-how. We try to protect this information with appropriate confidentiality and inventions
agreements with our employees, scientific advisors, consultants, and collaborators. We cannot be sure that these agreements will not be
breached, that we will be able to protect ourselves if they are breached, or that our trade secrets will not otherwise become known or
be independently discovered by competitors